Dataset Information

Escherichia albertii strain:YS-F1-1a, YS-F1-2, YS-F5-1a, YS-F12-1, YS-F13-1a, YS-F14-1c

ABSTRACT: Draft genome sequences of Escherichia albertii strains isolated from pig

PROVIDER: PRJDB8108 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other
	DRR185483_1.fastq.gz	Fastqsanger.gz
	DRR185483_2.fastq.gz	Fastqsanger.gz
	DRR185484_1.fastq.gz	Fastqsanger.gz
	DRR185484_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 13

Similar Datasets

Project description:BackgroundPharmacogenetic research has shown that genetic variation may influence statin responsiveness. Statins exert a variety of beneficial effects beyond lipid lowering, including antithrombotic effects, which contribute to the risk reduction of cardiovascular disease. Statins have been shown to influence the expression of coagulation factors II, V, VII, XII and XIII.AimData from a large randomized clinical trial of pravastatin, designed to show efficacy relative to usual care, were used to investigate whether a pharmacogenetic effect of polymorphisms in genes coding for coagulation factors II, V, VII, XII and XIII is associated with reduced fatal coronary heart disease (CHD) and nonfatal myocardial infarction, combined CHD and all-cause mortality.MethodsThe Genetics of Hypertension Associated Treatment is an ancillary study of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. The genotyped population in the lipid-lowering trial of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial included 9624 participants randomly assigned to pravastatin or to usual care. The efficacy of pravastatin in reducing risk of all-cause mortality, CHD and nonfatal myocardial infarction and combined CHD, was compared among genotype strata by examining an interaction term in a proportional hazards model.ResultsNone of the polymorphisms were associated with the clinical outcomes. For the F7 (-323) ins/del polymorphism there was no interaction with pravastatin for either outcome. For both the F5 Arg506Gln G>A (rs6025) polymorphism and F7 Arg353Gln G>A (rs6046) polymorphism there were no interactions with pravastatin in relation to all-cause mortality, but there were significant interactions with combined CHD [interaction hazard ratio = 1.33, 95% confidence interval (1.01-1.76) and interaction hazard ratio = 1.92, 95% confidence interval (1.00-3.65), respectively]. There were no interactions between the polymorphisms in the other coagulation genes and pravastatin in relation to any outcome.ConclusionPolymorphisms in anticoagulation genes (F5 and F7) seem to modify the efficacy of pravastatin in reducing risk of cardiovascular events.

Dataset Information

Escherichia albertii strain:YS-F1-1a, YS-F1-2, YS-F5-1a, YS-F12-1, YS-F13-1a, YS-F14-1c

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets